Weekly Specials

Author

李曉然小姐(Margaret Li)
分析師

本科主修市場行銷和英語,並於香港浸會大學獲得經濟學碩士學位。現為輝立証券持牌分析師,主要負責能源和公用事業等板塊的研究。曾在大型銀行、券商和資產管理公司工作,對於期貨和大宗商品衍生品領域擁有銷售、研究分析和市場推廣等工作經驗。

Margaret, a holder of a Bachelor`s degree in Marketing and English and a Master`s degree in Applied Economics from Hong Kong Baptist University, is currently employed as a licensed analyst at Phillip Securities. She specializes in conducting research focusing on the energy and utilities sectors. Prior to her current position, Margaret gained valuable work experience in a large bank, securities firm, and asset management companies. Her expertise lies in sales, research analysis, and marketing within the fields of futures and commodities derivatives.


Phone: 22776535  
Email Enquiry For Research Report and Business enquiry

CHICMAX (2145.HK) - Multi-brand layout strategy brings continuous revenue growth

Wednesday, September 3, 2025 Views3460
CHICMAX(2145)
Recommendation on  3 September 2025
Recommendation Accumulate
Price on Recommendation Date $92.200
Target Price $100.000

Overview

CHICMAX is a research-driven, multi-brand leader in the cosmetics industry. Founded in 2002, the company owns three core brands---KANS, ONE LEAF, and Baby Elephant---and has successfully established new growth drivers such as newpage and ARMIYO. It operates across four major segments: skincare, hair care, maternal and infant products, and cosmetics, with two self-built R&D centers and two supply chains worldwide.

Performance review

In H1 2025, the company's revenue reached RMB 4.108 billion (RMB, same below), representing a year-on-year increase of 17.3%. Net profit attributable to owners of the parent company was RMB 556 million, up 34.7% year-on-year. The growth in the company's revenue and profit was primarily driven by sustained revenue increase from the comprehensive multi-category, omni-channel strategy of the science-driven anti-aging skincare brand KANS, alongside a significant year-on-year revenue growth from the Chinese infant and child efficacy skincare brand newpage. Basic earnings per share were RMB 1.32, an increase of 30.7% year-on-year. An interim dividend of RMB 0.5 per share was declared, with cumulative dividend distributions exceeding RMB 1.2 billion since listing, reflecting the company's sustained high dividend payout ratio.

Implementing a multi-brand strategy, Baby Elephant has entered the children's cosmetics market

The flagship brand KANS maintained steady growth.
Launched in 2003, KANS is positioned as a "science-driven anti-aging" skincare brand, dedicated to meeting the evolving anti-aging needs of Asian women across all age groups, with a broad target customer base. In H1 2025, its revenue reached RMB 3.344 billion, representing a year-on-year increase of 14.3%. This growth was primarily driven by the overall upgrade of the KANS brand and expanded product categories, as well as sustained revenue growth across all channels. KANS accounted for 81.4% of the company's total revenue. The brand achieved widespread success across multiple platforms, with monthly GMV consistently ranking No. 1 among beauty brands on Douyin. It also secured the top spot on Douyin E-commerce's H1 2025 skincare brand overall rankings. The bestselling product, KANS Red Waist Series, remained highly popular, with cumulative sales exceeding 15 million sets across all channels. The KANS X-Peptide Ultra-Frequency Series generated cumulative sales of over RMB 200 million across all channels. The KANS brand is actively expanding into multiple categories, including men's series, haircare series, and makeup series, to meet diverse consumer needs.

ONE LEAF's Contribution to revenue continued to decline
Launched in 2004, ONE LEAF targets younger users. It employs advanced technology blended with natural ingredients to create effective and natural skincare products. In H1 2025, ONE LEAF was repositioned as a "science-backed skincare brand specializing in botanical extracts" and launched the Brightening Radiance Series and Black Tea Purifying Cleansing Cream. Its revenue for H1 2025 was RMB 89 million, a year-on-year decrease of 29%, accounting for 2.2% of total revenue. We believe that ONELEAF's brand revitalization is expected to attract more young consumers, which should help restore its revenue.

Baby Elephant pioneers the children's makeup Market
The company launched Baby Elephant in 2015, positioning it as a professional maternal and infant care brand tailored for Chinese children's skin, with the core philosophy of "minimalist ingredients, safe and effective," aiming to accompany every baby's healthy and happy growth. In 2024, it sold 400,000 units of children's makeup products and was certified by Frost & Sullivan as the top seller in China's online children's makeup market for that year. According to the 2024-2030 China Children's Makeup Industry Market In-Depth Assessment and Investment Profit Forecast Report released by Boyan Consulting and market research online, the market size of China's children's makeup industry has grown significantly in recent years and is expected to reach RMB 44 billion by 2025. Meanwhile, data from Magic Mirror Insights showed that the GMV of children's makeup products on Taobao and Tmall platforms increased by over 80% year-on-year in 2024. We believe the Chinese children's makeup market holds immense growth potential. With the widespread availability of internet access, many children now have their own mobile devices and can easily learn about makeup through platforms like WeChat, Douyin, and Rednote. The parenting attitudes of post-80s and post-90s generations have evolved (reflected in the extension of the "appearance economy" and the awakening of children's aesthetic education awareness), while innovations in product safety and fun, coupled with the two-child and three-child policies expanding the consumer base, have collectively driven the development of the children's makeup industry. CHICMAX has demonstrated keen insight by strategically entering the children's makeup market early, expanding its brand portfolio, and differentiating itself from other cosmetics companies to gain a competitive edge. In H1 2025, Baby Elephant generated revenue of RMB 159 million, a year-on-year decrease of 8.7%, primarily due to the initial effects of the brand's transformation and adjustment, which narrowed the decline. This revenue accounted for 3.9% of the company's total revenue.

Newpage Achieved Exponential Growth
Launched in 2022, Newpage is a pediatric efficacy skincare brand focused on babies with sensitive skin, positioned as "co-developed with medical professionals." In terms of product offerings, Newpage has expanded into three main categories: skincare, cleansing and bathing, and hygiene products. It caters to different age groups with segmented product lines, including infant series, school-age series, and adolescent series, comprehensively covering the children's skincare market. The hero product, Newpage Baby Soothing Cream, sold explosively during the 2025 618 shopping festival, with over 330,000 bottles sold, ranking No. 1 on Tmall in sales, positive reviews, and repurchase rate for children's face creams. In H1 2025, revenue reached RMB 397 million, a significant year-on-year increase of 146.5%. This growth was primarily driven by the rapid sales expansion of Newpage's star products, with online channel sales in the first half alone matching the full-year 2024 performance. Newpage accounted for 9.6% of the company's total revenue. We believe that Newpage has achieved substantial growth in both reputation and sales, and we are optimistic about its long-term growth potential.

Valuation and Investment Recommendation

According to data from the National Bureau of Statistics, China's total retail sales of consumer goods in H1 2025 reached RMB 24.5458 trillion, a year-on-year increase of 5%. Retail sales of cosmetics amounted to RMB 229.1 billion, up 2.9% year-on-year, exceeding the growth rate of H1 2024, demonstrating resilience in cosmetics consumption and a sustained upward trend.Data from Qingyan Intelligence shows that in July, the beauty and skincare category dominated Douyin's platform, accounting for 60.64% of GMV, with a year-on-year increase of 28.48% but a month-on-month decrease of 24.45%.The company's core brand, KANS, targets the mass skincare market, while Newpage exemplifies strong capabilities in incubating emerging brands. We expect further revenue growth from these two brands in the second half of the year. The company has achieved high growth in revenue and net profit attributable to parents for three consecutive years, supported by robust cash flow, providing a solid foundation for brand marketing and R&D investments. We forecast the company's operating revenue for 2025-2027 to be RMB 8.559 billion, RMB 10.613 billion, and RMB 12.947 billion, respectively, with EPS of RMB 2.63, RMB 3.11, and RMB 3.79. The corresponding P/E ratios are 32.3x, 27.2x, and 22.4x. We set a target price of HKD 100 for the company, corresponding to a 2025 expected P/E of 35x, and assign an "Accumulate" rating. (Current price as of Sep 1)

Risk factors

1) Downward macroeconomic situation;
2) Intensified industry competition;
3) Management changes;
4) New product promotion failing to meet expectations.

Financial Data

"Financial"Financial

Current Price as of: 1 Sep 2025
Source: PSHK Est.

Download PDF Version...

This report is produced and is being distributed in Hong Kong by Phillip Securities Group with the Securities and Futures Commission (“SFC”) licence under Phillip Securities (HK) LTD and/ or Phillip Commodities (HK) LTD (“Phillip”). Information contained herein is based on sources that Phillip believed to be accurate. Phillip does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The information is for informative purposes only and is not intended to or create/induce the creation of any binding legal relations. The information provided do not constitute investment advice, solicitation, purchase or sell any investment product(s). Investments are subject to investment risks including possible loss of the principal amount invested. You should refer to your Financial Advisor for investment advice based on your investment experience, financial situation, any of your particular needs and risk preference. For details of different product's risks, please visit the Risk Disclosures Statement on http://www.phillip.com.hk. Phillip (or employees) may have positions/ interests in relevant investment products. Phillip (or one of its affiliates) may from time to time provide services for, or solicit services or other business from, any company mentioned in this report. The above information is owned by Phillip and protected by copyright and intellectual property Laws. It may not be reproduced, distributed or published for any purpose without prior written consent from Phillip.
Top of Page
Contact Us
Please contact your account executive or call us now.
Research Department
Tel : (852) 2277 6846
Fax : (852) 2277 6565
Email : businessenquiry@phillip.com.hk

Enquiry & Support
Branches
The Complaint Procedures
About Us
Phillip Securities Group
Join Us
Phillip Network
Phillip Post
Phillip Channel
Latest Promotion
新闻稿
E-Check
Login
Investor Notes
Free Subscribe
Contact Us